Mirati Therapeutics, Inc.
PRC2 Inhibitors

Last updated:

Abstract:

The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

29 Jan 2019

Issue date:

4 Feb 2021